Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis

The article provides data on the place of methotrexate in accordance with international and national recommendations 2019– 2020 in the management of patients with rheumatoid and psoriatic arthritis. Data on the prevalence of these diseases, the effectiveness and tolerability of methotrexate accordin...

Full description

Saved in:
Bibliographic Details
Main Authors: N. V. Chichasova, A. M. Lila
Format: Article
Language:Russian
Published: Open Systems Publication 2021-06-01
Series:Лечащий Врач
Subjects:
Online Access:https://journal.lvrach.ru/jour/article/view/161
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850065128476639232
author N. V. Chichasova
A. M. Lila
author_facet N. V. Chichasova
A. M. Lila
author_sort N. V. Chichasova
collection DOAJ
description The article provides data on the place of methotrexate in accordance with international and national recommendations 2019– 2020 in the management of patients with rheumatoid and psoriatic arthritis. Data on the prevalence of these diseases, the effectiveness and tolerability of methotrexate according to randomized controlled and cohort studies are presented. The advantages of the subcutaneous form of methotrexate in terms of efficacy and tolerability for both rheumatoid and psoriatic arthritis are discussed. Data on the tolerance of the subcutaneous form of methotrexate from various manufacturers are presented.Analysis of literature data and the results of our own research indicate the need for early prescription of methotrexate in patients with rheumatoid arthritis and patients with peripheral joint lesions in psoriatic arthritis.Numerous studies confirm the effectiveness of methotrexate in rheumatoid arthritis in relation to the symptoms of the disease, both articular and non-articular, structural damage (slowing down X-ray progression), which is accompanied by an improvement in the patient’s functional abilities. With psoriatic arthritis, methotrexate is able to reduce the activity of arthritis, enthesitis, reduce skin manifestations, and improve the functional state of the patient. Treatment with methotrexate, when the clinical effect is achieved, is accompanied by a decrease in cardiovascular complications in inflammatory lesions of the joints.
format Article
id doaj-art-9810eb934da04aa5b52c0acde147e6bd
institution DOAJ
issn 1560-5175
2687-1181
language Russian
publishDate 2021-06-01
publisher Open Systems Publication
record_format Article
series Лечащий Врач
spelling doaj-art-9810eb934da04aa5b52c0acde147e6bd2025-08-20T02:49:05ZrusOpen Systems PublicationЛечащий Врач1560-51752687-11812021-06-0107425110.26295/OS.2020.12.42.002160Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritisN. V. Chichasova0A. M. Lila1FSBSI V. A. Nasonova Research Institute of RheumatologyFSBEI FPE RMACPE MON Russia Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian FederationThe article provides data on the place of methotrexate in accordance with international and national recommendations 2019– 2020 in the management of patients with rheumatoid and psoriatic arthritis. Data on the prevalence of these diseases, the effectiveness and tolerability of methotrexate according to randomized controlled and cohort studies are presented. The advantages of the subcutaneous form of methotrexate in terms of efficacy and tolerability for both rheumatoid and psoriatic arthritis are discussed. Data on the tolerance of the subcutaneous form of methotrexate from various manufacturers are presented.Analysis of literature data and the results of our own research indicate the need for early prescription of methotrexate in patients with rheumatoid arthritis and patients with peripheral joint lesions in psoriatic arthritis.Numerous studies confirm the effectiveness of methotrexate in rheumatoid arthritis in relation to the symptoms of the disease, both articular and non-articular, structural damage (slowing down X-ray progression), which is accompanied by an improvement in the patient’s functional abilities. With psoriatic arthritis, methotrexate is able to reduce the activity of arthritis, enthesitis, reduce skin manifestations, and improve the functional state of the patient. Treatment with methotrexate, when the clinical effect is achieved, is accompanied by a decrease in cardiovascular complications in inflammatory lesions of the joints.https://journal.lvrach.ru/jour/article/view/161rheumatoid arthritispsoriatic arthritisepidemiologyrecommendationsmethotrexatemonotherapyefficacytolerabilitycomorbiditysubcutaneous form
spellingShingle N. V. Chichasova
A. M. Lila
Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
Лечащий Врач
rheumatoid arthritis
psoriatic arthritis
epidemiology
recommendations
methotrexate
monotherapy
efficacy
tolerability
comorbidity
subcutaneous form
title Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
title_full Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
title_fullStr Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
title_full_unstemmed Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
title_short Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
title_sort methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
topic rheumatoid arthritis
psoriatic arthritis
epidemiology
recommendations
methotrexate
monotherapy
efficacy
tolerability
comorbidity
subcutaneous form
url https://journal.lvrach.ru/jour/article/view/161
work_keys_str_mv AT nvchichasova methotrexateinthetreatmentofrheumatoidarthritisandpsoriaticarthritis
AT amlila methotrexateinthetreatmentofrheumatoidarthritisandpsoriaticarthritis